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Abstract: The bacterial pathogen Helicobacter pylori commonly colonizes the human gastric 
mucosa during early childhood and persists throughout life. The organism has evolved multiple 
mechanisms for evading clearance by the immune system and, despite inducing inflammation 
in the stomach, the majority of infections are asymptomatic. H. pylori is the leading cause of 
peptic ulcer disease and gastric cancer. However, disease outcomes are related to the pattern 
and severity of chronic inflammation in the gastric mucosa, which in turn is influenced by 
both bacterial and host factors. Despite over 2 decades of intensive research, there remains 
an incomplete understanding of the circumstances leading to disease development, due to the 
 fascinating complexity of the host–pathogen interactions. There is accumulating data concern-
ing the virulence factors associated with increased risk of disease, and the majority of these 
have pro-inflammatory activities. Despite this, only a small proportion of those infected with 
virulent strains develop disease. Several H. pylori virulence factors have multiple effects on 
different cell types, including the induction of pro- and anti-inflammatory, immune stimulatory, 
and immune modulatory responses. The expression of multiple virulence factors is also often 
linked, making it difficult to assess the meaning of their effects in isolation. Overall, H. pylori 
is thought to usually modulate inflammation and limit acute damage to the mucosa, enabling 
the bacteria to persist. If this delicate balance is disturbed, disease may then develop.
Keywords: Helicobacter pylori, inflammation, mucosal immunity, peptic ulcer disease, gastric 
cancer
Introduction
Barry Marshall and Robin Warren were the first to isolate a spiral bacterium, now 
known as Helicobacter pylori, from inflamed mucosal tissue of the human stomach.1 
In most cases, the infection is asymptomatic. The severity and type of disease depend 
on the characteristics of the colonizing strain and how it interacts with the host to cause 
chronic inflammation. Many of the main H. pylori virulence factors have multiple 
effects on different cell types and may have both pro- and anti-inflammatory  activities. 
It is therefore necessary to assess the relative importance and net effects of these factors 
in order to understand the circumstances leading to disease development.
H. pylori infection
H. pylori has coevolved with humans over the last 60,000 years.2 It typically first 
 colonizes the gastric mucosa during early childhood and persists lifelong in the absence 
of effective eradication treatment.3 It is estimated that approximately 50% of the 
world’s population is colonized, although the prevalence differs between  countries. 
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Developing countries have a much higher infection rate 
than developed countries, and this is thought to be due to 
differences in living conditions and the use of antibiotics, 
especially in childhood.4 Globally, H. pylori prevalence is 
declining. In the US, approximately 10% of individuals under 
the age of 20 are infected compared to 40% over 60 years 
of age.5 This higher rate of H. pylori infection seen with 
increasing age is not due to acquisition of the infection at a 
later age, but a birth cohort effect.
H. pylori is found almost exclusively in humans. Other 
Helicobacter species are occasionally found in humans 
and these are thought to be acquired from domestic pets. 
The exact route of infectious transmission is not clear, but 
person-to-person transmission is likely to be a combination of 
fecal–oral and oral–oral routes. H. pylori strains are  usually 
isolated from gastric biopsy tissue, but it is also possible for 
the bacterium to be isolated from saliva, gastric reflux fluid, 
and vomitus.6
Consequences of H. pylori infection
Acute infection
Acute infectious symptoms (such as nausea, halitosis, 
 dyspepsia, and malaise) are experienced by most infected 
adults but the symptoms are variable. These tend to resolve 
within 2 weeks. Supporting evidence for the above is mainly 
from cases of deliberate  ingestion. When examined histologi-
cally, acute infection is accompanied by severe gastritis, char-
acterized by  infiltration of neutrophils and inflammatory cells 
with marked  persistent lymphocyte penetration. A reduction 
in stomach acid  secretion also occurs simultaneously.7 It 
is unknown whether children suffer similar symptoms or 
whether histological features are concordant.8
Chronic infection and disease outcome
Chronic H. pylori infection leads to local inflammation of 
the gastric mucosa (gastritis). Disease risk increases with 
the level of inflammation, but the pattern of  inflammation 
 determines the disease outcome. Host genetic factors, 
 bacterial virulence, environmental factors, and age of 
 infection all influence the distribution of resulting gastritis.8 
These complex and only partially understood interactions 
are thought to explain why only 15% of infected individuals 
develop disease in their lifetime.9
The most common and serious complications of 
H. pylori infection include peptic ulcer disease, distal gastric 
 adenocarcinoma, and primary gastric mucosa associated 
 lymphoid tissue (MALT) lymphoma. Other conditions 
 associated with H. pylori infection include dyspepsia, 
 atrophic gastritis, iron deficiency anemia, and idiopathic 
thrombocytopenia purpura. In contrast, epidemiological evi-
dence also suggests a protective association between H. pylori 
infection and disorders such as gastroesophageal reflux 
disease (GERD), esophageal adenocarcinoma,  inflammatory 
bowel disease, multiple sclerosis, and asthma.10,11
Peptic ulceration
Peptic ulcers are breaks in the lining of the duodenal or 
gastric mucosa, most commonly caused by H. pylori and 
nonsteroidal anti-inflammatory drugs. Peptic ulcer disease 
is associated with significant mortality and complications 
include hemorrhage and perforation. H. pylori eradication 
heals existing ulcers and prevents their recurrence.12
H. pylori is the causative agent in over 75% of  duodenal 
ulcer cases. Antral-predominant inflammation leads to 
increased gastric acid output (Figure 1). Gastric metaplasia of 
the duodenal epithelium then permits H. pylori to colonize and 
cause inflammation, which may lead to duodenal ulceration. 
H. pylori is also the leading cause of gastric ulcers, which 
develop in patients with pangastritis. Here the acid output 
is normal or reduced, thus preventing the development of 
duodenal ulcers, but gastric ulcers may develop. Premalignant 
lesions and gastric adenocarcinoma may also arise.2,13,14
Gastric adenocarcinoma
Gastric cancer is ranked the fifth most common malignancy 
worldwide with an estimated 100,000 new cases per year.15 
Most cases are found in Asia, with over two-thirds occurring 
in the People’s Republic of China.16 Gastric cancer is the third 
most common cause of cancer-related deaths, since initial 
 diagnosis is usually at a late stage.17,18 It can be divided into 
two subtypes depending on the location: cardia (arising from 
the gastroesophageal junction) and noncardia (arising from the 
distal stomach). Cardia gastric cancers share risk factors with 
esophageal adenocarcinoma, Barrett’s esophagus, obesity, and 
GERD.15 Noncardia gastric cancer is strongly  associated with 
H. pylori, and it is thought that up to 89% may be  attributed 
to the infection. Thus H. pylori has been classified as a 
human  carcinogen.19 The lifetime risk of an H. pylori-infected 
 individual developing gastric cancer is 1%–2%.14,20
There are two histological types of gastric adenocarcinoma: 
intestinal and diffuse. The intestinal type develops gradually, 
following a stepwise progression driven by inflammation. 
H. pylori infection of the normal gastric mucosa leads to a state 
of chronic gastritis, which later leads to atrophic gastritis (char-
acterized by gland loss and infiltration of  inflammatory cells), 
intestinal metaplasia (where gastric epithelial cells are replaced 
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with those of an intestinal type), dysplasia (neoplasia confined 
to epithelial cells), and finally adenocarcinoma.21 The diffuse 
type usually affects younger patients and is not associated 
with intestinal metaplasia. Although thought to be triggered 
by H. pylori infection, the exact mechanism is not known.17 
H. pylori eradication has been shown to reduce the incidence 
of atrophic gastritis but does not result in a reduction in gastric 
cancer incidence unless achieved before the appearance of 
premalignant changes.22
MALT lymphoma
H. pylori colonization is strongly linked to MALT  lymphoma.23 
Due to the rarity of this condition, the exact number of 
 individuals coinfected with H. pylori is not known but the 
condition occurs in less than 1% of those who are colonized. 
Low-grade B-cell MALT lymphomas normally regress 
 following H. pylori eradication treatment.24
Host response to H. pylori and its 
association with disease risk
H. pylori elicits a strong immune response, stimulating the 
expression of cytokines and chemokines from gastric epithelial 
cells. These factors attract neutrophils, macrophages, dendritic 
cells (DCs), natural killer (NK) cells, and lymphocytes,8,25 
and induce the release of reactive oxygen species (ROS) and 
 reactive nitrogen species (RNS). Gastric  carcinogenesis is 
associated with ROS/RNS-mediated DNA damage,  silencing 
of tumor suppressor genes via DNA methylation, histone epi-
genetic modification, and epithelial–mesenchymal  transition.26 
The level and nature of the immune response  varies and this 
affects the risk of disease development.27
Interactions of H. pylori with gastric 
epithelium
The surface of the gastric mucosa is covered by protective 
mucus consisting of a cell-associated layer (predominantly 
MUC1) and secreted mucin (mainly MUC5AC).28 This layer 
has a profound impact on H. pylori adhesion to the gastric 
mucosa. H. pylori interacts with mucin fucosylated Lewisb 
blood group antigen moieties via the BabA adhesin.29 During 
gastritis, there is an increase in sialylated mucin structures 
such as sialyl-Lewisx and sialyl-Lewisa, and these bind to the 
adhesin SabA.30 Recently, the LabA adhesin was  identified 
as binding a motif on MUC5AC.31 The mucus layer is also 
important for H. pylori motility; the organism reduces its 
viscosity in order to move through it.32 Mucins also have 
natural antibiotic activity against the bacterium,33 and 
H. pylori binding to MUC1 induces multiple effects on host 
cells including the modulation of inflammation.34
Innate immunity and inflammation
Pattern recognition receptors (PRRs) expressed by 
 gastric  epithelial cells interact with H. pylori and activate 
 inflammatory gene expression. These molecules, which 
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Figure 1 The effect of gastritis pattern on gastric acid production and associations with duodenal and gastric disease.
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include the toll-like receptors (TLRs) and nucleotide-binding 
oligomerization domain (NOD)-like receptors (NLRs), 
recognize pathogen-associated molecular patterns (PAMPs) 
such as lipopolysaccharide (LPS), flagellins, and cell wall 
peptides.35 Some H. pylori PAMPs are modified to weakly 
activate PRRs, since its tetra-acetylated LPS is poorly 
 recognized by TLR4, and the FlaA flagellin binds much less 
efficiently to TLR5.36 Unlike other bacteria, TLR2 appears 
to be the main receptor for H. pylori LPS, but TLR2 is also 
activated by other components (Table 1).37 Polymorphisms 
in TLR1, TLR2, TLR4, TLR5, and TLR9 genes have been 
associated with more severe gastritis and increased risk of 
premalignant pathology.38,39
Interaction of the cytotoxin-associated gene  pathogenicity 
island (cagPAI) encoded type IV secretion system (T4SS) 
with gastric epithelial cells results in the transfer of soluble 
Table 1 Major virulence factors and their effects on inflammation and the immune response
Virulence factor Pro-inflammatory roles Anti-inflammatory roles
CagA and the cagPAI-encoded  
type IV secretion system
Stimulates NF-κB activation in gastric epithelial cells,  
leading to expression of pro-inflammatory cytokines  
and chemokines; activation of MAPK signaling,  
leading to cell proliferation and inflammatory  
gene expression; disruption of epithelial cell junctions
CagA induces cell cycle arrest in T-cells;  
cagPAI-mediated signaling downregulates  
the expression of pro-inflammatory hBD1
VacA Induction or dysregulation of autophagy; induces IL-8  
production by monocytes and macrophages via p38  
MAPK signaling; activates mast cells and induces  
inflammatory cytokine expression; plays a role in  
maintaining colonization
Binds CD18 on human T-cells and directly  
inhibits the activation and proliferation  
of human B and T lymphocytes; exerts  
tolerizing effects on DCs to stimulate a  
Treg response; inhibits antigen presentation; 
inhibits DC maturation via effects on E2F1  
signaling; induces T-cells to express the  
Treg transcription factor Foxp3
DupA and the tfs4-encoded  
type IV secretion system
Induction of pro-inflammatory cytokine secretion  
by monocytes and epithelial cells
None reported
HP-NAP Activates neutrophils and induces ROS; stimulates TLR2;  
stimulates macrophages to produce IL-12 and IL-23;  
induces IL-6 production by mast cells; inhibits Th2  
responses and promotes the development of a Th1 response
None reported
Heat shock protein 60 Interacts with TLR2; stimulates macrophages and induces  
IL-12 and IL-23 expression
Induces a strong IL-10 response from  
human peripheral blood mononuclear cells
OipA Mediates closer interaction with gastric epithelium  
and induces pro-inflammatory cytokine expression;  
reduces IL-10 production  by DCs; disruption of  
epithelial cell tight junctions (with cagPAI signaling)
Inhibits DC maturation and promotes the  
differentiation of naïve T-cells into Tregs
Peptidyl prolyl cis-,  
transisomerase (HP0175)
Interacts with TLR4; stimulates a Th17 response None reported
Fucosylated Lewis blood  
group antigens (LPS moieties)
Interact with major adhesins; mediate closer interaction  
and exposure of epithelial cells to H. pylori virulence factors
Interaction with DC-SIGN on DCs to  
increase IL-10 expression and suppress  
IL-6; modulation of Th1/Th2 balance
SabA Interacts with sialylated receptors on neutrophils  
to induce ROS production; mediates closer interaction  
and exposure of epithelial cells to H. pylori virulence factors
None reported
Gamma-glutamyl transpeptidase Induces NF-κB activation, IL-8 production, and ROS by  
gastric epithelial cells; gastric epithelial cell death;  
stimulates a Th17 response
Potent T-cell suppressant activity; induces  
T-cells to express the Treg transcription  
factor Foxp3; upregulates COX2 
expression  
in T-cells which modulates Th1 response
Abbreviations: IL, interleukin; DC, dendritic cell; H. pylori, Helicobacter pylori; ROS, reactive oxygen species; TLR, toll-like receptor; Th, T-helper; LPS, lipopolysaccharide; 
NAP, neutrophil-activating protein.
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peptidoglycan components into the cytoplasm, NOD1 
activation, and pro-inflammatory gene expression.40 The 
largest NLR subfamily includes the NLRPs, which are the 
scaffolding proteins of inflammasomes. NLRPs interact 
with adaptor proteins leading to the activation of caspase-1, 
which controls the maturation of inflammatory cytokines 
such as IL-1β and IL-18.41 There is increased expression of 
these factors and other NLRP3-related molecules in infected 
gastric tissue.39,42
Autophagy, the pathway for breakdown and removal of 
damaged cellular components, is an important homeostatic 
mechanism which regulates inflammatory signaling.43 
Dysregulation of autophagy has been reported to result 
in increased production of ROS and DNA damage. This 
leads to accumulations of damaged organelles, changes in 
cell metabolism, and carcinogenesis.44 H. pylori-mediated 
induction of autophagy has been reported;45,46 however, more 
virulent H. pylori isolates rapidly downregulate autophagy in 
gastric epithelial and monocytic cells lines.47 Characterization 
of the H. pylori B128 7.13 strain, which causes gastric cancer 
in Mongolian gerbils, revealed a mutation in a peptidoglycan 
deacetylase gene (pgdA). This led to reduced autophagy in 
vitro and cancer development in animals.48
Secreted antimicrobial peptides are produced in response 
to H. pylori. Elevated levels of human beta defensin 2 
(hBD2), hBD3, hBD4, adrenomedullin, angiogenin, alpha 
defensins 1, 2, and 3, and the human cationic antimicrobial 
peptide 18 (LL-37) are present in the gastric mucosa of 
H. pylori-infected patients and/or infected human gastric 
 epithelial cells in vitro.49–54
As a consequence of H. pylori interactions with the 
epithelium, pro-inflammatory chemokines and cytokines, 
including IL-8, IL-1β, tumor necrosis factor alpha (TNFα), 
IL-6, IL-12, CCL2-5, CCL20, and CXCL1-3, are upregu-
lated in the infected gastric mucosa.55,56 Gene polymorphisms 
 resulting in increased expression of pro-inflammatory cyto-
kines (IL-6, IL-8, TNFα, IL-1β), or reduced expression of 
anti- inflammatory cytokines (IL-10), are associated with 
higher risk of disease.27,57,58 The presence of chemokines leads 
to the recruitment of immune cells, including neutrophils, 
macrophages, DCs, NK cells, and lymphocytes.2 Neutrophils 
contribute to gastritis by secreting inflammatory cytokines and 
releasing tissue damaging factors from neutrophilic  granules. 
They also phagocytose bacteria, and within the phago-
lysosomes the bacteria are exposed to bactericidal factors, 
including myeloperoxidase and matrix metalloproteinases 
which degrade cell walls and proteins, and ROS and RNS, 
which induce DNA damage. H. pylori prevents the oxidative 
burst and can survive intracellularly within neutrophils.59 
Helicobacter-infected neutrophil-depleted mice appear to be 
colonized at the same densities as normal mice.60 These data 
imply that neutrophils may play a lesser role in protective 
immunity, but contribute to mucosal damage.
Macrophage-depleted mice have a significantly reduced 
H. pylori gastritis severity.61 Both M1 and M2 macrophages 
are present in the infected gastric mucosa.62 M1 macrophages 
secrete pro-inflammatory cytokines and nitric oxide and 
have potent bactericidal activity compared with M2 mac-
rophages, which promote cell proliferation and tissue repair.63 
H. pylori is able to survive phagocytosis by macrophages, 
since it induces the fusing together of phagosomes to form 
megasomes without lysosomal fusion.64 The megasomes 
provide a protected intracellular niche and may even contrib-
ute to the persistence of infection.65 H. pylori is also able to 
neutralize the released ROS via catalase activity, and arginase 
production by the bacteria inhibits nitric oxide production.66,67 
Chronic exposure to ROS and RNS, however, results in host 
cell DNA damage and favors cancer development.
Mast cells are also present at higher frequencies in the 
H. pylori-infected human gastric mucosa.68 The role of these 
cells has not been widely studied, but they may be involved in 
tissue repair, inflammation, and vaccine-mediated clearance 
of the infection.69
DCs in H. pylori-infected gastric tissue tend to be of a 
myeloid type (mDCs) and express DC-SIGN and high  levels of 
HLA-DR, but are semi-mature and tolerogenic.70–75 Together 
with the DC response, macrophage-derived  cytokines also 
have an important influence on the  development and balance 
of the adaptive immune response.76 It has recently been shown 
that both human gastric epithelial cells and gastric mucosal 
DCs produce retinoic acid (RA), an important factor that 
regulates inflammation. When infected with H. pylori, how-
ever, mucosal RA production is impaired, leading to increased 
inflammation and possibly resulting in incresed risk of peptic 
ulceration and gastric carcinogenesis.77
Despite recent interest in invariant lymphoid and NK cell 
populations there is very little data on these in the context 
of H. pylori infection. NKT cells are more abundant in the 
infected gastric mucosa, and a larger NK cell population 
was detected in the peripheral blood of infected donors.78,79 
How these cell types contribute to disease is not understood; 
however, NK cell-derived perforin and granzymes may 
cause damage to host cells. NK cells respond to incuba-
tion with H. pylori or its secreted products by secreting 
inflammatory cytokines such as interferon-gamma (IFNγ) 
and TNFα.80
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Adaptive immunity
Strong IgG and IgA antibody responses are present in 
H. pylori-infected individuals and these may trigger 
 autoimmunity.66 Molecular mimicry by H. pylori induces 
antibodies that react with host antigens in the gastric mucosa, 
such as the parietal cell H+, K+-ATPase.81 Such autoreactive 
antibodies are frequently present in the serum of infected 
patients, and these may increase local inflammation and 
damage in the stomach or elsewhere.82
H. pylori infection induces a vigorous T-cell response, 
which includes both CD4+ and CD8+ cells. The gastric 
mucosa of infected humans and mice contains increased 
numbers of CD8+ cells and these contribute to inflammation 
and disease.83 More is known about the CD4+ T-helper (Th) 
response. The main Th subsets induced by H. pylori infection 
are pro-inflammatory Th17 and Th1 and anti-inflammatory 
regulatory T-cell (Treg) populations; however, Th2 and Th22 
responses have also been reported.84–88 Th-derived cytokines 
orchestrate the host response, having an impact on H. pylori-
induced inflammation and immunity, as well as playing an 
important role in determining H. pylori-associated disease 
risk.
Th1 cells secrete cytokines IFNγ and TNFα, which stimu-
late macrophages to secrete further pro-inflammatory factors 
and have more bactericidal activity.89 Th17 cells secrete IL-
17A, IL-17F, IL-21, and IL-22, and stimulate the expression 
of antimicrobial peptides, ROS, RNS, and chemokines. This 
leads to increased inflammation and  neutrophil recruitment.90 
H. pylori-induced expression of B-cell activating factor of 
TNF family (BAFF) by macrophages is important for the 
differentiation of Th17 cells.76 In H. pylori-infected mice, 
a Th17 response is observed in addition to the Th1 response, 
leading to more severe gastritis.91
In the infected human and mouse gastric mucosa, the 
severity of gastritis correlates with the number of Th1 and 
Th17 cells.92–94 Although a strong Th1 response may con-
tribute to carcinogenesis, there is evidence that a high 
Th1 response leads to a better prognosis for gastric cancer 
patients due to stronger antitumor immunity.95 On the other 
hand,  high-level Th17 and Th22 responses are associated 
with gastric cancer progression and poor survival,  possibly 
due to the role of their cytokines in angiogenesis and tumor 
invasiveness.96 Gastric Th1 cells from the antrum of patients 
with peptic ulcer disease provide help for B-cell antibody iso-
type switching, induce epithelial cells to express higher levels 
of MHC class II, and also have H. pylori-specific cytolytic 
activity.94 They are proposed to contribute to disease via cyto-
toxicity against antigen-presenting epithelial cells, and may 
also promote autoimmune reactions such as in autoimmune 
gastritis and gastric MALT lymphoma.81,94 T-cell clones from 
patients with MALT lymphoma, however, are commonly 
Th0 rather than Th1 types. These have a markedly reduced 
cytotoxic activity against B-cells and an impaired ability to 
induce apoptosis in T-cells. This may explain the unchecked 
B-cell expansion in MALT lymphoma.97
H. pylori has multiple mechanisms for directing the 
immune system away from a pro-inflammatory T-cell 
response and toward a suppressive Treg response.98 Increased 
numbers of Tregs are observed in the gastric mucosa and 
peripheral blood of H. pylori-infected patients, and peptic 
ulceration is more frequently found in those with reduced 
Treg numbers in their gastric mucosa.56,84,92,99 Tregs may act 
by secreting cytokines such as IL-10 and transforming growth 
factor beta to modulate inflammation, or they may act via 
contact-mediated mechanisms.100 H. pylori influences DCs 
to promote the differentiation of naïve T-cells into Tregs. 
Such responses are reported to protect against extra-gastric 
immune and inflammatory conditions including asthma and 
inflammatory bowel disease.74,101
In addition to Treg induction, H. pylori utilizes many 
other mechanisms to modulate the immune and inflamma-
tory response. Several virulence factors have anti- as well 
as pro-inflammatory functions (Table 1), and expression 
of B7-H1 is upregulated in gastric epithelial cells during 
H. pylori infection. Interaction with this molecule suppresses 
T-cell activity.102
Virulence factors and inflammation
H. pylori produces numerous virulence factors, many of 
which are highly polymorphic, phase variable, genetically 
linked, and/or have diverse and sometimes opposing func-
tions. This diversity, together with the complexity of the host 
immune response, makes it difficult to define clearly the rela-
tive roles of individual virulence factors in H. pylori- mediated 
inflammation and disease. Pro- and anti-inflammatory influ-
ences of some of the best-studied H. pylori virulence factors 
are briefly summarized in this section.
The cag pathogenicity island and CagA
The cagPAI is a 40 kb horizontally transmitted segment of 
DNA. It encodes a T4SS, with CagL at the tip of the  needle-like 
structure which binds to α5β1 integrin on host cells.103 CagA, 
an immunodominant 120-145 kDa protein, is injected into 
cells through the T4SS together with  peptidoglycan  peptides. 
This process activates NF-κB, triggering the secretion of 
pro-inflammatory cytokines and chemokines, most notably 
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IL-8. Once inside the host cell, CagA is rapidly tyrosine 
phosphorylated at its EPIYA (Glu-Pro-Ile-Tyr-Ala) motifs 
by Src kinases and then interacts with the SHP-2 cellular 
phosphatase. This ultimately leads to cytoskeletal changes 
via actin rearrangement.104 Unphosphorylated CagA also 
interacts with numerous targets inside the host cell includ-
ing the tight junction protein ZO-1 (causing tight junction 
disruption) and E-cadherin (disrupting E-cadherin/β-catenin 
complexes to promote β-catenin mediated upregulation of 
genes with oncogenic potential).105,106 Taken together,  cagPAI 
activity drives a scattering/elongation, or “ hummingbird”, 
 phenotype and pro-inflammatory responses in gastric 
 epithelial cells. However, cagPAI-mediated NF-κB activa-
tion also downregulates the expression of the antimicrobial 
and pro-inflammatory defensin hBD1, and the activation 
of SHP-2 by CagA prevents EGFR-mediated expression of 
hBD-3.53,107 Downregulation of these β-defensins may help 
promote the persistence of CagA-positive H. pylori strains.
The cagPAI may be present fully, partially, or not at all. 
Strains with a functional cag T4SS are strongly associated 
with increased gastric cancer risk. The cagA gene sequence 
is itself polymorphic. EPIYA motifs may be categorized as 
EPIYA-A, B, C, or D depending on their flanking sequences, 
with EPIYA-A, B, and C found in Western CagA types and 
EPIYA-A, B, and D found in East Asian CagA. A larger 
number of EPIYA-C motifs or the presence of an EPIYA-
D increases interactions with SHP-2, and is  associated 
with a higher risk of intestinal metaplasia and gastric 
 cancer.108 Strains lacking CagA may induce inflammation 
via other  cagPAI-dependent mechanisms. If the T4SS is 
 functional, peptidoglycan peptides enter the cell and activate 
 NOD1-mediated signaling.40 Additionally, interaction of 
CagL with the α5β1 integrin is sufficient to activate NF-κB 
and induce IL-8 expression.109
Vacuolating cytotoxin (VacA)
Virtually all H. pylori strains possess the vacA gene but it 
is highly polymorphic, with two alternative allelic variants 
for the signal (s1/s2), intermediate (i1/i2), and mid- (m1/m2) 
regions. The mid-region plays a role in host cell binding, 
and m1 forms are able to bind a wider range of cell types 
than m2. s2 and i2 VacA have reduced activity compared to 
the s1 and i1 variants.110,111 VacA is a pore-forming toxin, 
originally named for its ability to induce vacuolation in 
gastric epithelial cells in vitro. A myriad of other functions 
have also been attributed to it, including the induction of 
epithelial cell apoptosis, autophagy, and inhibition of T-cell 
activation (Table 1).46,112,113
The vacA s1 and i1 alleles are associated with increased 
risk of peptic ulceration, atrophy, and gastric adenocarci-
noma, but genetic linkage between these alleles and the pres-
ence of cagA makes it difficult to determine with certainty 
the contribution of each individual factor.111 There is also 
functional linkage between VacA and CagA, for example, 
VacA induces apoptosis in gastric epithelial cells, but CagA 
blocks this activity and can also prevent VacA gaining 
access into host cells.114,115 This may protect the host cell to 
which the bacterium has adhered, while allowing continued 
VacA-mediated disruption of more distant cells. Conversely, 
VacA inhibits the induction of the hummingbird phenotype 
by CagA.116 Recently, VacA and another secreted H. pylori 
protein, γ-glutamyl transferase have been shown to  tolerize 
DCs, promoting Treg responses and protecting against asthma 
in a mouse model.117,118 Since both s1i1m1 and s2i2m2 VacA 
can tolerize DCs, this anti-inflammatory function may be 
one reason for the otherwise unexplained maintenance of 
apparently nonfunctional type 2 toxin variants in the H. 
pylori genome.
DupA and tfs4
H. pylori genomes contain regions of low GC content and 
high diversity, known as “plasticity zones”. The number and 
contents of PZs vary between strains, and several PZ-specific 
genes are associated with disease. Of these, one of the best 
studied is the duodenal ulcer-promoting gene, dupA. The tfs4 
gene cluster comprises dupA and other vir homologues which 
are thought to encode a type IV secretion system.119
Although dupA was initially identified as a duodenal 
 ulcer-promoting virulence factor, numerous subsequent 
 conflicting studies have left the role of dupA in disease 
unclear. This is likely due to the requirement for other com-
ponents of the tfs4 to produce a functional type IV secretion 
system, making dupA alone an imperfect marker.120,121 The 
presence of dupA in clinical H. pylori isolates is associ-
ated with increased IL-8 levels in the antrum of infected 
individuals.122,123
H. pylori neutrophil-activating protein (HP-NAP)
HP-NAP is a highly conserved dodecameric 150 kDa protein, 
named for its ability to stimulate endothelial adhesion and 
production of oxygen radicals by neutrophils. The protein is 
also a neutrophil chemottractant and stimulates these cells 
to produce pro-inflammatory cytokines and chemokines. 
Since neutrophil infiltration is a dominant characteristic of 
H. pylori gastritis, HP-NAP may play a central role in H. 
pylori-associated disease. HP-NAP may also associate with 
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the outer membrane of intact bacteria and play a role in 
binding to host mucin carbohydrates.124,125
Adhesins
Adherent bacteria might be expected to induce stronger 
inflammatory responses than nonadherent bacteria. H. pylori 
possesses several major adhesins including the blood group 
antigen binding adhesin (BabA), sialic acid binding adhesin 
(SabA), and OipA.
BabA is expressed by a subset of H. pylori strains, and it 
binds to difucosylated Leb blood group antigens on host epi-
thelial cells.29 BabA may facilitate close association with the 
epithelium for delivery of other virulence factors, and indeed 
babA2-positive strains are associated with increased gastric 
mucosal granulocyte infiltration and IL-8 expression.126
sabA is a phase-variable gene that may be switched “on” 
or “off ”. SabA allows H. pylori to adhere to  sialylated Lewis 
antigens, which are present during gastritis.30 BabA plays 
the major role in bacterial adhesion soon after  colonization, 
and SabA becomes the predominant adhesin once chronic 
inflammation is established. Colonization with SabA-
producing strains is associated with increased risk of gastric 
cancer, atrophy, and intestinal metaplasia; however, there 
is a  negative association between SabA expression and 
 neutrophil infiltration.127
OipA is another phase-variable adhesin, and it has 
 several other putative functions including the induction of 
actin stress fiber formation and IL-8 production by epithelial 
cells. OipA shares some activities and host cell signaling 
pathways with the cagPAI, and IL-8 expression may be 
induced  synergistically. There is also OipA-specific  signaling, 
 however. While “on” OipA is associated with increased risk 
of duodenal ulcer and gastric cancer, defining the relative 
roles of cagPAI and oipA is not straightforward because oipA 
“on” strains are also likely to be cagPAI-positive.128,129
Conclusion
H. pylori infection strongly stimulates gastric mucosal 
inflammation and both the innate and acquired immune 
response. The usual consequence of H. pylori infection is 
chronic asymptomatic gastritis, probably because the bacteria 
have adapted to evade and suppress the immune response. 
The inflammatory response is important in the  development 
of gastric adenocarcinoma; however, there is  growing 
 evidence that other aspects of the local and systemic response 
are also central to disease pathogenesis. It may ultimately 
be possible to develop prognostic tests based on these 
parameters, along with bacterial virulence types, to predict 
who is at risk of developing gastric cancer. However, since 
many of the major virulence factors have both pro- and 
 anti-inflammatory activities, further research is necessary to 
gain a complete understanding of the circumstances leading 
to disease occurrence.
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